The Manufacturers Life Insurance Company raised its stake in Rubius Therapeutics, Inc. (NASDAQ:RUBY) by 4.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,021 shares of the company’s stock after purchasing an additional 973 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Rubius Therapeutics were worth $190,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Baillie Gifford & Co. raised its stake in shares of Rubius Therapeutics by 10.2% during the fourth quarter. Baillie Gifford & Co. now owns 4,710,061 shares of the company’s stock worth $35,749,000 after purchasing an additional 436,200 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Rubius Therapeutics by 2.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 235,622 shares of the company’s stock worth $1,181,000 after buying an additional 4,967 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Rubius Therapeutics by 4.6% in the 4th quarter. Bank of New York Mellon Corp now owns 157,810 shares of the company’s stock worth $1,198,000 after acquiring an additional 6,934 shares during the period. HITE Hedge Asset Management LLC purchased a new stake in shares of Rubius Therapeutics in the fourth quarter valued at about $674,000. Finally, California Public Employees Retirement System increased its stake in shares of Rubius Therapeutics by 4.4% during the third quarter. California Public Employees Retirement System now owns 75,700 shares of the company’s stock worth $379,000 after acquiring an additional 3,200 shares during the period. Institutional investors own 93.74% of the company’s stock.
Shares of NASDAQ RUBY opened at $24.05 on Friday. The company has a current ratio of 7.15, a quick ratio of 7.15 and a debt-to-equity ratio of 0.43. The company’s 50-day moving average price is $20.32 and its 200 day moving average price is $10.90. Rubius Therapeutics, Inc. has a 52 week low of $4.20 and a 52 week high of $38.71. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -11.24 and a beta of 2.37.
RUBY has been the topic of a number of analyst reports. SVB Leerink lifted their price objective on Rubius Therapeutics from $4.00 to $20.00 and gave the company a “market perform” rating in a report on Monday, March 22nd. HC Wainwright increased their price objective on Rubius Therapeutics from $28.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, March 22nd. Morgan Stanley upped their price target on shares of Rubius Therapeutics from $5.00 to $10.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 19th. Finally, Zacks Investment Research downgraded shares of Rubius Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $20.00.
In other news, major shareholder Ventures Fund Iv Gene Flagship bought 210,000 shares of the business’s stock in a transaction that occurred on Friday, March 19th. The stock was purchased at an average price of $29.00 per share, with a total value of $6,090,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director David R. Epstein sold 89,233 shares of the firm’s stock in a transaction dated Monday, February 8th. The stock was sold at an average price of $14.88, for a total transaction of $1,327,787.04. Following the sale, the director now directly owns 4,726,220 shares in the company, valued at $70,326,153.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 121,637 shares of company stock worth $1,943,292. 58.40% of the stock is owned by insiders.
About Rubius Therapeutics
Rubius Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers.
Further Reading: What economic reports are most valuable to investors?
Want to see what other hedge funds are holding RUBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rubius Therapeutics, Inc. (NASDAQ:RUBY).
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.